Skip to main content
x
About searching

Search results

  1. Amgen packs up in Claudin6

    … Car-T Ph1 in solid tumours (NCT04503278) Data at ESMO 2023; ph2 in testicular germ cell tumours to start 2024 …

    - 07/12/2024 - 12:32

  2. IO Biotech looks for an interim injection

    … & UBC + Keytruda (uncontrolled) Preliminary data at ESMO 2023; more data expected autumn 2024 PN-E40 …

    - 06/27/2024 - 20:11

  3. ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems

    … and a secondary endpoint in Evoke-01. Source: ESMO 2023 & ASCO 2024. Conferences …

    - 06/01/2024 - 22:08

  4. EHA 2024 preview – Novartis doubles up

    … Anti-CD123 NK cell engager S146 Had data at ESMO 2023 Roche Englumafusp alfa …

    - 05/20/2024 - 18:11

  5. J&J speeds into new bladder cancer trial

    … pts with FGFR alterations Ph1 data at ESMO 2023: 87% CR rate in 15 pts in cohort 3 (BCG-naive) … BCG-experienced pts with FGFR mutations Data at ESMO 2023: 72% reduction in risk of recurrence/death in 73 … Ph2 Sunrise-1 in high-risk BCG-unresponsive pts, data at ESMO 2023: 77% CR rate in 30 pts Source: …

    - 04/23/2024 - 13:00

  6. BioNTech has some cancer convincing to do

    … Car-T N/A Ph1/2 in solid tumours Data at ESMO 2023 showed promising efficacy, but with tox …

    - 03/21/2024 - 13:20

  7. AACR 2024 preview – clinical highlights and lowlights

    … inhibitor 1L glioblastoma CT044 Had data at ESMO 2023 Cadonilimab Akeso Anti-PD-1 x CTLA-4 …

    - 03/07/2024 - 15:52

  8. Revolution pushes home its pan-KRAS advantage

    … Medicines Multi-KRAS inhibitor Ph1 data at ESMO 2023 Ph3 could begin in 2024 in NSCLC & pancreatic …

    - 02/28/2024 - 15:37

  9. BioNTech bails out Autolus

    … capacity Data with automated production at ESMO 2023 ; pivotal trial in germ cell tumours due to start …

    - 02/08/2024 - 15:05

  10. Jazz joins the KRAS band with Redx deal

    … which produced promising data – with caveats – at ESMO 2023. Quanta is taking an interesting approach, with … KRAS G12D siRNA Ph2 in pancreatic cancer; ESMO 2023: no difference in OS vs chemo MRTX1133 … KRAS G12D inhibitor Lacklustre ph1 data at ESMO 2023 (1/18 PRs) ASP3082 Astellas KRAS G12D …

    - 02/08/2024 - 13:03